Skip to main content

CAR T-Cell Therapy

Treatment With Anakinra After Initially Receiving Tocilizumab for Cytokine Release Syndrome

Ailin Kim, PharmD, BCOP; Monank Patel, PharmD, BCOP; Walter Domingo, PharmD, BCOP; Theresa Latchford, RN, MS; Matthew Frank, MD, PhD

Locoregional CAR T Cells for the Treatment of CNS Tumors in Children: Investigational Drug Service Pharmacy Activities

Nicholas A. Vitanza, MD; Michelle Choe, MD; Christopher Brown, BA; Adam Beebe, BA; Ada Kong, PharmD; Lisa Rogers, PharmD, et al.

Anakinra Used in a Patient with Diffuse Large B-Cell Lymphoma and Steroid-Refractory Immune Effector Cell–Associated Neurotoxicity Syndrome: Case Report

Drew A. Wells, PharmD, BCPS; Kori Holman, PharmD, BCOP; Brion Randolph, MD; Dennis Marjoncu, PharmD, BCOP

Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma

Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma

Second-Line Axicabtagene Ciloleucel Therapy Improves Outcomes in Patients with Large B-Cell Lymphoma: ZUMA-7

Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma

A Review of CAR T-Cell Therapies Approved for the Treatment of Relapsed and Refractory B-Cell Lymphomas

Drew A. Wells, PharmD, BCPS; Jenna Summerlin, PharmD; Zachery Halford, PharmD, BCOP, BCPPS

CAR T-Cell Therapy: Review of the Newest Weapon in the Battle Against Hematologic Malignancies

Dennis Marjoncu, PharmD, BCOP

Meeting Highlights

ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma

1
2

Page 1 of 2
Results 1 - 10 of 14